Enanta Pharma (ENTA) Tops Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Baird Cuts Price Target on Enanta Pharma (ENTA) Despite Bottom-Line Beat
February 9, 2016 7:28 AM ESTBaird remains Neutral on Enanta Pharmaceuticals (NASDAQ: ENTA), and cut the price target to $22.00 (from $36.00), following the company's 1Q. Non-GAAP EPS was reported at $1.36, beating consensus estimates of $1.13. The company ended the quarter with $236.6M in cash, which management expects will last for the... More



